KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV)
CUSIP: 483497103
Q1 2026 13F Holders as of 31 Mar 2026
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 50,580,036
- Total 13F shares
- 59,639
- Share change
- -13,987
- Total reported value
- $1,199,908
- Price per share
- $20.13
- Number of holders
- 12
- Value change
- -$281,062
- Number of buys
- 5
- Number of sells
- 2
Quarterly Holders Quick Answers
What is CUSIP 483497103?
CUSIP 483497103 identifies KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
- Previous quarter: Q4 2025
Recent filing periods for CUSIP 483497103:
Top shareholders of KALV - KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VR Adviser, LLC |
13F
|
Company |
13%
|
6,728,985
|
$108,673,108 | — | 31 Dec 2025 | |
| Bong Y. Koh |
3/4/5
|
10%+ Owner |
10%
|
5,089,354
|
$97,308,448 | -$3,691,148 | 25 Mar 2026 | |
| Nimish P. Shah |
3/4/5
|
10%+ Owner |
10%
|
5,089,354
|
$97,308,448 | -$3,691,148 | 25 Mar 2026 | |
| Venrock Healthcare Capital Partners EG, L.P. |
3/4/5
|
10%+ Owner |
10%
|
5,089,354
|
$97,308,448 | -$3,691,148 | 25 Mar 2026 | |
| Venrock Healthcare Capital Partners III, L.P. |
3/4/5
|
10%+ Owner |
10%
|
5,089,354
|
$97,308,448 | -$3,691,148 | 25 Mar 2026 | |
| VHCP Co-Investment Holdings III, LLC |
3/4/5
|
10%+ Owner |
10%
|
5,089,354
|
$97,308,448 | -$3,691,148 | 25 Mar 2026 | |
| VHCP Management EG, LLC |
3/4/5
|
10%+ Owner |
10%
|
5,089,354
|
$97,308,448 | -$3,691,148 | 25 Mar 2026 | |
| VHCP Management III, LLC |
3/4/5
|
10%+ Owner |
10%
|
5,089,354
|
$97,308,448 | -$3,691,148 | 25 Mar 2026 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
10%
|
5,039,867
|
$81,393,852 | — | 31 Dec 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
9.4%
|
4,768,712
|
$77,014,699 | — | 31 Dec 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
13D/G
|
Company |
9.9%
from 13D/G
|
4,573,530
|
$73,862,510 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.4%
|
3,754,148
|
$60,629,492 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
13D/G
|
Company |
5.9%
from 13D/G
|
2,896,666
|
$46,781,156 | — | 31 Dec 2025 | |
| Capital World Investors |
13F
13D/G
|
Company |
6.4%
from 13D/G
|
2,808,583
|
$45,358,615 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13D/G
13F
|
Company |
5.5%
|
2,781,902
|
$44,930,777 | $0 | 05 Jan 2026 | |
| Frazier Life Sciences Public Fund, L.P. |
13D/G
|
— |
6.9%
|
3,466,521
|
$42,222,226 | +$12,986,864 | 01 Nov 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
5%
|
2,509,020
|
$40,520,674 | — | 31 Dec 2025 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
4.8%
|
2,427,118
|
$39,197,956 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
3.8%
|
1,921,092
|
$31,025,636 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.8%
|
1,911,691
|
$30,873,810 | — | 31 Dec 2025 | |
| Vestal Point Capital, LP |
13F
13D/G
|
Company |
1.5%
from 13D/G
|
1,890,000
|
$30,523,500 | — | 31 Dec 2025 | |
| Kynam Capital Management, LP |
13F
|
Company |
3.6%
|
1,810,954
|
$29,246,907 | — | 31 Dec 2025 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
3.5%
|
1,768,508
|
$28,561,404 | — | 31 Dec 2025 | |
| EMERALD ADVISERS, LLC |
13F
|
Company |
2.7%
|
1,340,495
|
$21,648,994 | — | 31 Dec 2025 | |
| Octagon Capital Advisors LP |
13F
|
Company |
2.5%
|
1,273,333
|
$20,564,328 | — | 31 Dec 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
2.3%
|
1,171,755
|
$18,923,843 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
944,077
|
$15,251,132 | — | 31 Dec 2025 | |
| EMERALD MUTUAL FUND ADVISERS TRUST |
13F
|
Company |
1.7%
|
855,461
|
$13,815,695 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.7%
|
835,304
|
$13,490,160 | — | 31 Dec 2025 | |
| Elmind Capital, LP |
13F
|
Company |
1.6%
|
801,300
|
$12,940,995 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.6%
|
800,000
|
$12,920,000 | — | 31 Dec 2025 | |
| BARCLAYS PLC |
13F
|
Company |
1.4%
|
700,573
|
$11,314,253 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.4%
|
700,228
|
$11,308,696 | — | 31 Dec 2025 | |
| Squadron Capital Management LLC |
13F
|
Company |
1.4%
|
700,000
|
$11,305,000 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
1.4%
|
695,175
|
$11,227,076 | — | 31 Dec 2025 | |
| GREAT POINT PARTNERS LLC |
13F
|
Company |
1.4%
|
685,632
|
$11,072,957 | — | 31 Dec 2025 | |
| Freestone Grove Partners LP |
13F
|
Company |
1.3%
|
633,019
|
$10,223,257 | — | 31 Dec 2025 | |
| Benjamin L. Palleiko |
3/4/5
|
CHIEF EXECUTIVE OFFICER, Director |
—
mixed-class rows
|
690,736
mixed-class rows
|
$9,144,577 | -$1,806,389 | 06 Mar 2026 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.77%
|
389,813
|
$6,295,479 | — | 31 Dec 2025 | |
| Spruce Street Capital LP |
13F
|
Company |
0.77%
|
387,968
|
$6,265,683 | — | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
0.76%
|
382,400
|
$6,175,760 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.74%
|
371,993
|
$6,007,687 | — | 31 Dec 2025 | |
| Blue Owl Capital Holdings LP |
13F
|
Company |
0.71%
|
360,000
|
$5,814,000 | — | 31 Dec 2025 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.71%
|
356,802
|
$5,762,352 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.7%
|
351,973
|
$5,684,365 | — | 31 Dec 2025 | |
| Skandinaviska Enskilda Banken AB (publ) |
13F
|
Company |
0.69%
|
351,305
|
$5,682,358 | — | 31 Dec 2025 | |
| Hennion & Walsh Asset Management, Inc. |
13F
|
Company |
0.68%
|
341,819
|
$5,520,377 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.64%
|
324,369
|
$5,238,559 | — | 31 Dec 2025 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.6%
|
305,880
|
$4,939,959 | — | 31 Dec 2025 | |
| Thomas Andrew Crockett |
3/4/5
|
CEO, Director |
—
mixed-class rows
|
322,315
mixed-class rows
|
$4,648,801 | — | 17 Feb 2024 |
Institutional Holders of KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) as of Q1 2026
As of 31 Mar 2026,
KalVista Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (KALV) was held by
12 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
59,639 shares.
The largest 10 holders included
SG Americas Securities, LLC, Diversified Trust Co, PSP Research LLC, Cerro Pacific Wealth Advisors LLC, SIGNATUREFD, LLC, GF FUND MANAGEMENT CO. LTD., Versant Capital Management, Inc, GAMMA Investing LLC, Farther Finance Advisors, LLC, and TOTH FINANCIAL ADVISORY CORP.
This page lists
12
institutional shareholders reporting positions in this security
for the Q1 2026 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2026 vs Q4 2025 Across Filers
Q4 2025 holders
161
Q1 2026 holders
12
Holder diff
-149
| Investor | Q4 2025 Shares | Q1 2026 Shares | Share Diff | Share Chg % | Q4 2025 Value $ | Q1 2026 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.